Drug Trial Radar · NCT03179904
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Aug 3, 2017
Primary completion
Jul 30, 2024
Study completion Mar 13, 2026
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic). FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used in endocrine therapy either lower the amount of estrogen made by the body or blocks the use of estrogen by the tumor cells. This may help stop the growth of tumor cells that need estrogen to grow. Giving FASN inhibitor TVB-2640 and trastuzumab in combination with paclitaxel or endocrine therapy may help control the disease in patients with HER2 positive breast cancer.
Conditions
- Advanced Breast Carcinoma
- HER2-Positive Breast Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- HER2-positive Breast Cancer
Interventions
AnastrozoleDrug
Given PO
DenifanstatDrug
Given PO
ExemestaneDrug
Given PO
FulvestrantDrug
Given IM
EchocardiographyProcedure
Undergo ECHO
LetrozoleDrug
Given PO
PaclitaxelDrug
Given IV
TrastuzumabBiological
Given IV
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Biospecimen CollectionProcedure
Undergo blood sample collection
BiopsyProcedure
Undergo biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: 14 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona
Mayo Clinic in Florida
Jacksonville, Florida
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.